NCT06788171View on ClinicalTrials.gov

PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Colorectal Cancer Liver Metastasis
Interventions
RADIATION

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy

PULSAR (SBRT): A targeted radiation therapy delivering 5-10 Gy/fraction every 3 weeks (q3w) to the gross tumor volume (GTV), for 3 times.

DRUG

Bevacizumab

Bevacizumab: 5mg/kg, d1, q3w, 6 cycles.

DRUG

Capecitabine

Capecitabine: 1000mg/m2, d1-14, bid, q3w, 6 cycles.

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2, d1, q3w, 6 cycles.

DRUG

Sintilimab

Sintilimab: 200mg, d1, q3w, 6 cycles.

Trial Locations (1)

350014

Fujian Cancer Hospital, Fuzhou

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV